B. Poiesz, F. Ruscetti, A. Gazdar, P. Bunn, J. Minna et al., Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proceedings of the National Academy of Sciences, vol.77, issue.12, pp.7415-7419, 1980.
DOI : 10.1073/pnas.77.12.7415

E. Wattel, J. Vartanian, C. Pannetier, and S. Wain-hobson, Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy, J Virol, vol.69, pp.2863-2868, 1995.

G. De-the and R. Bomford, An HTLV-I Vaccine: Why, How, for Whom?, AIDS Research and Human Retroviruses, vol.9, issue.5, pp.381-386, 1993.
DOI : 10.1089/aid.1993.9.381

C. Hlela, S. Shepperd, N. Khumalo, and G. Taylor, The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown, AIDS Rev, vol.11, pp.205-214, 2009.

K. Verdonck, E. Gonzalez, S. Van-dooren, A. Vandamme, G. Vanham et al., Human T-lymphotropic virus 1: recent knowledge about an ancient infection, The Lancet Infectious Diseases, vol.7, issue.4, pp.266-281, 2007.
DOI : 10.1016/S1473-3099(07)70081-6

C. Bangham, The immune control and cell-to-cell spread of human T-lymphotropic virus type 1, Journal of General Virology, vol.84, issue.12, pp.3177-3189, 2003.
DOI : 10.1099/vir.0.19334-0

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983.
DOI : 10.1212/WNL.33.11.1444

M. Osame, A. Igata, and M. Matsumoto, HTLV-I-associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings, Hematol Rev, vol.3, pp.271-284, 1990.

F. Umehara, S. Izumo, M. Nakagawa, A. Ronquillo, K. Takahashi et al., Immunocytochemical Analysis of the Cellular Infiltrate in the Spinal Cord Lesions in HTLV-I-Associated Myelopathy, Journal of Neuropathology and Experimental Neurology, vol.52, issue.4, pp.424-430, 1993.
DOI : 10.1097/00005072-199307000-00010

M. Nakagawa, K. Nakahara, Y. Maruyama, M. Kawabata, I. Higuchi et al., Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis, Journal of Neurovirology, vol.2, issue.5, pp.345-355, 1996.
DOI : 10.3109/13550289609146899

U. Oh and S. Jacobson, Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy, Neurologic Clinics, vol.26, issue.3, pp.781-797, 2008.
DOI : 10.1016/j.ncl.2008.03.008

A. Lezin, N. Gillet, S. Olindo, A. Signate, N. Grandvaux et al., Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients, Blood, vol.110, issue.10, pp.3722-3728, 2007.
DOI : 10.1182/blood-2007-04-085076

G. Taylor, P. Goon, Y. Furukawa, H. Green, A. Barfield et al., Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial, Retrovirology, vol.3, issue.1, p.63, 2006.
DOI : 10.1186/1742-4690-3-63

H. Rafatpanah, A. Rezaee, M. Etemadi, R. Hosseini, B. Khorram et al., The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran, Journal of Neuroimmunology, vol.250, issue.1-2, pp.87-93, 2012.
DOI : 10.1016/j.jneuroim.2012.05.004

U. Oh, Y. Yamano, C. Mora, J. Ohayon, F. Bagnato et al., Interferon-?1a therapy in human T-lymphotropic virus type I-associated neurologic disease, Annals of Neurology, vol.168, issue.4, pp.526-534, 2005.
DOI : 10.1002/ana.20429

Y. Furukawa, J. Fujisawa, M. Osame, M. Toita, S. Sonoda et al., Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP), Blood, vol.80, pp.1012-1016, 1992.

C. Tendler, S. Greenberg, J. Burton, D. Danielpour, S. Kim et al., Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis, Journal of Cellular Biochemistry, vol.26, issue.4, pp.302-311, 1991.
DOI : 10.1002/jcb.240460405

M. Nagai, K. Usuku, W. Matsumoto, D. Kodama, N. Takenouchi et al., Analysis Of Htlv-I Proviral Load In 202 Ham/Tsp Patients And 243 Asymptomatic Htlv-I Carriers: High Proviral Load Strongly Predisposes To Ham/Tsp, Journal of Neurovirology, vol.4, issue.6, pp.586-593, 1998.
DOI : 10.3109/13550289809114225

Y. Kuroda and M. Matsui, Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy, Journal of Neuroimmunology, vol.42, issue.2, pp.223-226, 1993.
DOI : 10.1016/0165-5728(93)90014-P

S. Nakamura, I. Nagano, M. Yoshioka, S. Shimazaki, J. Onodera et al., Detection of tumor necrosis factor-alpha-positive cells in cerebrospinal fluid of patients with HTLV-I-associated myelopathy, pp.127-130, 1993.

N. Nishimoto, K. Yoshizaki, N. Eiraku, K. Machigashira, H. Tagoh et al., Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis, Journal of the Neurological Sciences, vol.97, issue.2-3, pp.183-193, 1990.
DOI : 10.1016/0022-510X(90)90217-B

K. Jones, C. Petrow-sadowski, Y. Huang, D. Bertolette, and F. Ruscetti, Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells, Nature Medicine, vol.174, issue.4, pp.429-436, 2008.
DOI : 10.1182/blood.V99.1.88

Y. Koyanagi, Y. Itoyama, N. Nakamura, K. Takamatsu, J. Kira et al., In Vivo Infection of Human T-Cell Leukemia Virus Type I in Non-T Cells, Virology, vol.196, issue.1, pp.25-33, 1993.
DOI : 10.1006/viro.1993.1451

N. Harris and F. Ronchese, The role of B7 costimulation in T-cell immunity, Immunology and Cell Biology, vol.77, issue.4, pp.304-311, 1999.
DOI : 10.1084/jem.185.1.177

N. Pardigon, C. Cambouris, N. Bercovici, F. Lemaitre, R. Liblau et al., Delayed and Separate Costimulation In Vitro Supports the Evidence of a Transient "Excited" State of CD8+ T Cells During Activation, The Journal of Immunology, vol.164, issue.9, pp.4493-4499, 2000.
DOI : 10.4049/jimmunol.164.9.4493

R. Lal, D. Rudolph, C. Dezzutti, P. Linsley, and H. Prince, Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands, J Immunol, vol.157, pp.1288-1296, 1996.

T. Takamoto, M. Makino, M. Azuma, T. Kanzaki, M. Baba et al., HTLV-I-infected T cells activate autologous CD4+ T cells susceptible to HTLV-I infection in a co-stimulatory molecule-dependent fashion, European Journal of Immunology, vol.69, issue.6, pp.1427-1432, 1997.
DOI : 10.1002/eji.1830270620

T. Chang, C. Jabs, R. Sobel, V. Kuchroo, and A. Sharpe, Studies in B7-Deficient Mice Reveal a Critical Role for B7 Costimulation in Both Induction and Effector Phases of Experimental Autoimmune Encephalomyelitis, The Journal of Experimental Medicine, vol.161, issue.5, pp.733-740, 1999.
DOI : 10.1084/jem.186.9.1585

M. Racke, D. Scott, L. Quigley, G. Gray, R. Abe et al., Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis., Journal of Clinical Investigation, vol.96, issue.5, pp.2195-2203, 1995.
DOI : 10.1172/JCI118274

S. Miller, C. Vanderlugt, D. Lenschow, J. Pope, N. Karandikar et al., Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE, Immunity, vol.3, issue.6, pp.739-745, 1995.
DOI : 10.1016/1074-7613(95)90063-2

E. Zeinstra, N. Wilczak, D. Keyser, and J. , Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2, Journal of Neuroimmunology, vol.135, issue.1-2, pp.166-171, 2003.
DOI : 10.1016/S0165-5728(02)00462-9

B. Bauvois, J. Nguyen, R. Tang, C. Billard, and J. Kolb, Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1, Biochemical Pharmacology, vol.78, issue.5, pp.514-522, 2009.
DOI : 10.1016/j.bcp.2009.05.005

URL : https://hal.archives-ouvertes.fr/hal-00497271

K. Genc, D. Dona, and A. Reder, Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy., Journal of Clinical Investigation, vol.99, issue.11, pp.2664-2671, 1997.
DOI : 10.1172/JCI119455

E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel et al., Effects of interferon-?? on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-?? treatment in patients with multiple sclerosis, Multiple Sclerosis, vol.14, issue.2, pp.166-176, 2008.
DOI : 10.1177/1352458507081342

C. Espejo, L. Brieva, G. Ruggiero, J. Rio, X. Montalban et al., IFN-?? treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing???remitting multiple sclerosis, Multiple Sclerosis, vol.10, issue.6, pp.630-635, 2004.
DOI : 10.1191/1352458504ms1094oa

R. Rudick and S. Goelz, Beta-interferon for multiple sclerosis, Experimental Cell Research, vol.317, issue.9, pp.1301-1311, 2011.
DOI : 10.1016/j.yexcr.2011.03.002

S. Izumo, I. Goto, Y. Itoyama, T. Okajima, S. Watanabe et al., Interferon-alpha is effective in HTLV-I-associated myelopathy: A multicenter, randomized, double-blind, controlled trial, Neurology, vol.46, issue.4, pp.1016-1021, 1996.
DOI : 10.1212/WNL.46.4.1016

K. Shibayama, T. Nakamura, K. Nagasato, S. Shirabe, M. Tsujihata et al., Interferon-alpha treatment in HTLV-I-associated myelopathy, Journal of the Neurological Sciences, vol.106, issue.2, pp.186-192, 1991.
DOI : 10.1016/0022-510X(91)90256-7

M. Osame, Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP, 1990.

M. Grassi, V. Olavarria, A. Kruschewsky-rde, R. Mascarenhas, I. Dourado et al., Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP, Journal of Medical Virology, vol.2, issue.7, pp.1269-1274, 2011.
DOI : 10.1002/jmv.22087

V. Adaui, K. Verdonck, I. Best, E. Gonzalez, M. Tipismana et al., SYBR Green???based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: Influence of clinical status, sex, and familial relatedness, Journal of Neurovirology, vol.12, issue.6, pp.456-465, 2006.
DOI : 10.1080/13550280601039634

S. Olindo, A. Lezin, P. Cabre, H. Merle, M. Saint-vil et al., HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: A marker of disease progression, Journal of the Neurological Sciences, vol.237, issue.1-2, pp.53-59, 2005.
DOI : 10.1016/j.jns.2005.05.010

E. Gotuzzo, J. Cabrera, L. Deza, K. Verdonck, A. Vandamme et al., Clinical Characteristics of Patients in Peru with Human T Cell Lymphotropic Virus Type 1???Associated Tropical Spastic Paraparesis, Clinical Infectious Diseases, vol.39, issue.7, pp.939-944, 2004.
DOI : 10.1086/423957

M. Lima, R. Bica, and A. Araujo, Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis, Journal of Neurology, Neurosurgery & Psychiatry, vol.76, issue.2, pp.294-296, 2005.
DOI : 10.1136/jnnp.2004.035709

P. Norris, D. Hirschkorn, D. Devita, T. Lee, and E. Murphy, Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells, Virulence, vol.1, issue.1, pp.19-28, 2010.
DOI : 10.1128/JVI.00887-07

Y. Furukawa, C. Bangham, G. Taylor, J. Weber, and M. Osame, Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Clinical and Experimental Immunology, vol.1, issue.2, pp.307-316, 2000.
DOI : 10.1007/s000180050067

Z. Liu, C. Pelfrey, A. Cotleur, J. Lee, and R. Rudick, Immunomodulatory effects of interferon beta-1a in multiple sclerosis, Journal of Neuroimmunology, vol.112, issue.1-2, pp.153-162, 2001.
DOI : 10.1016/S0165-5728(00)00403-3

V. Ramgolam, Y. Sha, K. Marcus, N. Choudhary, L. Troiani et al., B Cells as a Therapeutic Target for IFN-?? in Relapsing-Remitting Multiple Sclerosis, The Journal of Immunology, vol.186, issue.7, pp.4518-4526, 2011.
DOI : 10.4049/jimmunol.1000271

M. Saito, T. Matsuzaki, Y. Satou, J. Yasunaga, K. Saito et al., In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), Retrovirology, vol.6, issue.1
DOI : 10.1186/1742-4690-6-19

Y. Yamano, N. Araya, T. Sato, A. Utsunomiya, K. Azakami et al., Abnormally High Levels of Virus-Infected IFN-??+CCR4+CD4+CD25+ T Cells in a Retrovirus-Associated Neuroinflammatory Disorder, PLoS ONE, vol.79, issue.10, p.6517, 2009.
DOI : 10.1371/journal.pone.0006517.s002

O. Neill, S. Cao, Y. Hamel, K. Doodes, P. Hutas et al., Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis, J Immunol, vol.179, pp.5109-5116, 2007.

H. Morbach, V. Wiegering, P. Richl, T. Schwarz, N. Suffa et al., Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis, Arthritis & Rheumatism, vol.224, issue.11, pp.3458-3466, 2011.
DOI : 10.1002/art.30569

V. Kuchroo, M. Das, J. Brown, A. Ranger, S. Zamvil et al., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy, Cell, vol.80, issue.5, pp.707-718, 1995.
DOI : 10.1016/0092-8674(95)90349-6

J. Brown, R. Greenwald, S. Scott, A. Schweitzer, A. Satoskar et al., T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major, European Journal of Immunology, vol.32, issue.6, pp.1764-1772, 2002.
DOI : 10.1002/1521-4141(200206)32:6<1764::AID-IMMU1764>3.0.CO;2-V

M. Mbow, G. Dekrey, and R. Titus, Leishmania major induces differential expression of costimulatory molecules on mouse epidermal cells, European Journal of Immunology, vol.31, issue.5, pp.1400-1409, 2001.
DOI : 10.1002/1521-4141(200105)31:5<1400::AID-IMMU1400>3.0.CO;2-J

Y. Furukawa, D. Mandelbrot, P. Libby, A. Sharpe, and R. Mitchell, Association of B7-1 Co-Stimulation with the Development of Graft Arterial Disease, The American Journal of Pathology, vol.157, issue.2, pp.473-484, 2000.
DOI : 10.1016/S0002-9440(10)64559-2

S. Newton, Y. Ding, C. Chung, Y. Chen, J. Lomas-neira et al., Sepsis-Induced Changes in Macrophage Co-Stimulatory Molecule Expression: CD86 as a Regulator of Anti-Inflammatory IL-10 Response, Surgical Infections, vol.5, issue.4, pp.375-383, 2004.
DOI : 10.1089/sur.2004.5.375

A. Nolan, H. Kobayashi, B. Naveed, A. Kelly, Y. Hoshino et al., Differential Role for CD80 and CD86 in the Regulation of the Innate Immune Response in Murine Polymicrobial Sepsis, PLoS ONE, vol.177, issue.8, p.6600, 2009.
DOI : 10.1371/journal.pone.0006600.t001

A. Nolan, M. Weiden, A. Kelly, Y. Hoshino, S. Hoshino et al., CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial Sepsis, American Journal of Respiratory and Critical Care Medicine, vol.177, issue.3, pp.301-308, 2008.
DOI : 10.1164/rccm.200703-515OC

F. Sellebjerg, J. Jensen, and L. Ryder, Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis, Journal of Neuroimmunology, vol.84, issue.2, pp.179-187, 1998.
DOI : 10.1016/S0165-5728(97)00261-0

A. Svenningsson, L. Dotevall, S. Stemme, and O. Andersen, Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease, Journal of Neuroimmunology, vol.75, issue.1-2, pp.59-68, 1997.
DOI : 10.1016/S0165-5728(96)00234-2

A. Windhagen, J. Newcombe, F. Dangond, C. Strand, M. Woodroofe et al., Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions, Journal of Experimental Medicine, vol.182, issue.6, pp.1985-1996, 1995.
DOI : 10.1084/jem.182.6.1985

S. Sawcer, G. Hellenthal, M. Pirinen, C. Spencer, N. Patsopoulos et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, Nature, vol.48, issue.7359, pp.214-219, 2011.
DOI : 10.1038/nature10251

URL : https://hal.archives-ouvertes.fr/hal-00996686

M. Keir, M. Butte, G. Freeman, and A. Sharpe, PD-1 and Its Ligands in Tolerance and Immunity, Annual Review of Immunology, vol.26, issue.1, pp.677-704, 2008.
DOI : 10.1146/annurev.immunol.26.021607.090331

A. Sharpe and G. Freeman, THE B7???CD28 SUPERFAMILY, Nature Reviews Immunology, vol.12, issue.2, pp.116-126, 2002.
DOI : 10.1038/35069118

P. Montanheiro, A. De-oliveira, J. Smid, L. Fukumori, I. Olah et al., The Elevated Interferon Gamma Production is an Important Immunological Marker in HAM/TSP Pathogenesis, Scandinavian Journal of Immunology, vol.269, issue.suppl 2, pp.403-407, 2009.
DOI : 10.1111/j.1365-3083.2009.02291.x

T. Luna, S. Santos, M. Nascimento, M. Porto, A. Muniz et al., Effect of TNF-?? production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals, Brazilian Journal of Medical and Biological Research, vol.44, issue.11, pp.1134-1140, 2011.
DOI : 10.1590/S0100-879X2011007500140

B. Moens, D. Decanine, S. Menezes, R. Khouri, G. Silva-santos et al., Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN-?? in HTLV-1-Associated Myelopathy, PLoS Neglected Tropical Diseases, vol.113, issue.7, p.1729, 2012.
DOI : 10.1371/journal.pntd.0001729.s001

I. Moldovan, R. Rudick, A. Cotleur, S. Born, J. Lee et al., Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression, Journal of Neuroimmunology, vol.141, issue.1-2, pp.132-140, 2003.
DOI : 10.1016/S0165-5728(03)00221-2

H. Panitch, R. Hirsch, A. Haley, and K. Johnson, EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON, The Lancet, vol.329, issue.8538, pp.893-895, 1987.
DOI : 10.1016/S0140-6736(87)92863-7

A. Cross, T. Girard, K. Giacoletto, R. Evans, R. Keeling et al., Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation., Journal of Clinical Investigation, vol.95, issue.6, pp.2783-2789, 1995.
DOI : 10.1172/JCI117982

J. Park, R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu et al., B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance, Blood, vol.116, issue.8, pp.1291-1298, 2010.
DOI : 10.1182/blood-2010-01-265975

S. Hirata, S. Senju, H. Matsuyoshi, D. Fukuma, Y. Uemura et al., Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand, The Journal of Immunology, vol.174, issue.4, pp.1888-1897, 2005.
DOI : 10.4049/jimmunol.174.4.1888

J. Zhao, G. Freeman, G. Gray, L. Nadler, and L. Glimcher, A cell type-specific enhancer in the human B7.1 gene regulated by NF- kappaB, Journal of Experimental Medicine, vol.183, issue.3, pp.777-789, 1996.
DOI : 10.1084/jem.183.3.777

A. Paun and P. Pitha, The IRF family, revisited, Biochimie, vol.89, issue.6-7, pp.744-753, 2007.
DOI : 10.1016/j.biochi.2007.01.014

S. Waddell, S. Popper, K. Rubins, M. Griffiths, P. Brown et al., Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells, PLoS ONE, vol.5, issue.3, p.9753, 2010.
DOI : 10.1371/journal.pone.0009753.s010

H. Pahl, Activators and target genes of Rel/NF-??B transcription factors, Oncogene, vol.18, issue.49, pp.6853-6866, 1999.
DOI : 10.1038/sj.onc.1203239

G. Chen and D. Goeddel, TNF-R1 Signaling: A Beautiful Pathway, Science, vol.296, issue.5573, pp.1634-1635, 2002.
DOI : 10.1126/science.1071924

J. Li, A. Colovai, R. Cortesini, and N. Suciu-foca, Cloning and functional characterization of the 5???-regulatory region of the human CD86 gene, Human Immunology, vol.61, issue.5, pp.486-498, 2000.
DOI : 10.1016/S0198-8859(00)00099-9

H. Panitch, Systemic ??-Interferon in Multiple Sclerosis, Archives of Neurology, vol.44, issue.1, pp.61-63, 1987.
DOI : 10.1001/archneur.1987.00520130047016

Y. Satou, J. Yasunaga, M. Yoshida, and M. Matsuoka, HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells, Proceedings of the National Academy of Sciences, vol.103, issue.3, pp.720-725, 2006.
DOI : 10.1073/pnas.0507631103

I. Azran, Y. Schavinsky-khrapunsky, and M. Aboud, Role of tax protein in human T-cell leukemia virus type-I leukemogenicity, Retrovirology, vol.1, issue.1, p.20, 2004.
DOI : 10.1186/1742-4690-1-20

R. Szymocha, H. Akaoka, C. Brisson, P. Beurton-marduel, A. Chalon et al., Astrocytic Alterations Induced by HTLV Type 1-Infected T Lymphocytes: A Role for Tax-1 and Tumor Necrosis Factor ??, AIDS Research and Human Retroviruses, vol.16, issue.16, pp.1723-1729, 2000.
DOI : 10.1089/08892220050193218

R. Szymocha, H. Akaoka, M. Dutuit, C. Malcus, M. Didier-bazes et al., Human T-Cell Lymphotropic Virus Type 1-Infected T Lymphocytes Impair Catabolism and Uptake of Glutamate by Astrocytes via Tax-1 and Tumor Necrosis Factor Alpha, Journal of Virology, vol.74, issue.14, pp.6433-6441, 2000.
DOI : 10.1128/JVI.74.14.6433-6441.2000

D. Brown, F. Nelson, E. Reinherz, and D. Diamond, The human interferon-?? gene contains an inducible promoter that can be transactivated by tax I and II, European Journal of Immunology, vol.48, issue.8, pp.1879-1885, 1991.
DOI : 10.1002/eji.1830210815

J. Podojil, A. Kohm, and S. Miller, CD4+ T Cell Expressed CD80 Regulates Central Nervous System Effector Function and Survival during Experimental Autoimmune Encephalomyelitis, The Journal of Immunology, vol.177, issue.5, pp.2948-2958, 2006.
DOI : 10.4049/jimmunol.177.5.2948

S. Marckmann, E. Wiesemann, R. Hilse, C. Trebst, M. Stangel et al., Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis, Clinical and Experimental Immunology, vol.103, issue.3, pp.499-506, 2004.
DOI : 10.1016/S0165-5728(00)00403-3

S. Santos, A. Porto, A. Muniz, A. De-jesus, E. Magalhaes et al., Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers, BMC Infectious Diseases, vol.43, issue.5, 2004.
DOI : 10.1046/j.1365-3083.1996.d01-9.x

R. Colisson, L. Barblu, C. Gras, F. Raynaud, R. Hadj-slimane et al., Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells, Blood, vol.115, issue.11, pp.2177-2185, 2010.
DOI : 10.1182/blood-2009-06-224741

URL : https://hal.archives-ouvertes.fr/hal-00456470

S. Tattermusch, J. Skinner, D. Chaussabel, J. Banchereau, M. Berry et al., Systems Biology Approaches Reveal a Specific Interferon-Inducible Signature in HTLV-1 Associated Myelopathy, PLoS Pathogens, vol.37, issue.1, p.1002480, 2012.
DOI : 10.1371/journal.ppat.1002480.s014

J. Feng, T. Misu, K. Fujihara, H. Saito, T. Takahashi et al., Interferon-?? significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP, Journal of Neuroimmunology, vol.141, issue.1-2, pp.170-173, 2003.
DOI : 10.1016/S0165-5728(03)00219-4

B. Macchi, I. Faraoni, A. Mastino, D. Onofrio, C. Romeo et al., Protective effect of interferon ? on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood, Cancer Immunology Immunotherapy, vol.81, issue.2, pp.97-104, 1993.
DOI : 10.1007/BF01517041

D. Onofrio, C. Perno, C. Mazzetti, P. Graziani, G. Calio et al., Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon, British Journal of Cancer, vol.57, issue.5, pp.481-488, 1988.
DOI : 10.1038/bjc.1988.111

B. Arnason, Long-term experience with interferon beta-1b (Betaferon??) in multiple sclerosis, Journal of Neurology, vol.77, issue.S3, pp.28-33, 2005.
DOI : 10.1007/s00415-005-2014-2

B. Weinstock-guttman, M. Ramanathan, and R. Zivadinov, Interferon-?? treatment for relapsing multiple sclerosis, Expert Opinion on Biological Therapy, vol.13, issue.9, pp.1435-1447, 2008.
DOI : 10.1053/jhep.2001.26371

K. Mckeage, Interferon-??-1b, CNS Drugs, vol.122, issue.1, pp.787-792, 2008.
DOI : 10.2165/00023210-200822090-00005

D. Mirowska, J. Skierski, A. Paz, M. Koronkiewicz, J. Zaborski et al., Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-?-1a treatment in multiple sclerosis patients, Journal of Neurology, vol.250, issue.10, pp.1229-1236, 2003.
DOI : 10.1007/s00415-003-0170-9

M. Revel, J. Chebath, M. Mangelus, S. Harroch, and G. Moviglia, Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients, Mult Scler, vol.1, issue.1, pp.5-11, 1995.

A. Noronha, A. Toscas, and M. Jensen, Interferon ?? decreases T cell activation and interferon ?? production in multiple sclerosis, Journal of Neuroimmunology, vol.46, issue.1-2, pp.145-153, 1993.
DOI : 10.1016/0165-5728(93)90244-S

J. Van-weyenbergh, P. Lipinski, A. Abadie, D. Chabas, U. Blank et al., Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients, J Immunol, vol.161, pp.1568-1574, 1998.

T. Zhao, J. Yasunaga, Y. Satou, M. Nakao, M. Takahashi et al., Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-??B, Blood, vol.113, issue.12, pp.2755-2764, 2009.
DOI : 10.1182/blood-2008-06-161729

B. Barbeau and J. Mesnard, Making Sense out of Antisense Transcription in Human T-Cell Lymphotropic Viruses (HTLVs), Viruses, vol.3, issue.12, pp.456-468, 2011.
DOI : 10.3390/v3050456

C. Karp, A. Van-boxel-dezaire, A. Byrnes, and L. Nagelkerken, Interferon-?? in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?, Current Opinion in Neurology, vol.14, issue.3, pp.361-368, 2001.
DOI : 10.1097/00019052-200106000-00016

X. Wang, M. Chen, K. Wandinger, G. Williams, and S. Dhib-jalbut, IFN-??-1b Inhibits IL-12 Production in Peripheral Blood Mononuclear Cells in an IL-10-Dependent Mechanism: Relevance to IFN-??-1b Therapeutic Effects in Multiple Sclerosis, The Journal of Immunology, vol.165, issue.1, pp.548-557, 2000.
DOI : 10.4049/jimmunol.165.1.548

Z. Marijanovic, J. Ragimbeau, J. Van-der-heyden, G. Uze, and S. Pellegrini, Comparable potency of IFN??2 and IFN?? on immediate JAK/STAT activation but differential down-regulation of IFNAR2, Biochemical Journal, vol.407, issue.1, pp.141-151, 2007.
DOI : 10.1042/BJ20070605

URL : https://hal.archives-ouvertes.fr/hal-00478796

L. Roisman, D. Jaitin, D. Baker, and G. Schreiber, Mutational Analysis of the IFNAR1 Binding Site on IFN??2 Reveals the Architecture of a Weak Ligand???Receptor Binding-site, Journal of Molecular Biology, vol.353, issue.2, pp.271-281, 2005.
DOI : 10.1016/j.jmb.2005.08.042

P. Domanski, O. Nadeau, L. Platanias, E. Fish, M. Kellum et al., Differential Use of the beta L Subunit of the Type I Interferon (IFN) Receptor Determines Signaling Specificity for IFNalpha 2 and IFNbeta, Journal of Biological Chemistry, vol.273, issue.6, pp.3144-3147, 1998.
DOI : 10.1074/jbc.273.6.3144

N. De-weerd, J. Vivian, T. Nguyen, N. Mangan, J. Gould et al., Structural basis of a unique interferon-?? signaling axis mediated via the receptor IFNAR1, Nature Immunology, vol.180, issue.9, pp.901-907, 2013.
DOI : 10.4049/jimmunol.0902314

G. Stark, I. Kerr, B. Williams, R. Silverman, and R. Schreiber, HOW CELLS RESPOND TO INTERFERONS, Annual Review of Biochemistry, vol.67, issue.1, pp.227-264, 1998.
DOI : 10.1146/annurev.biochem.67.1.227

M. Muller, J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki et al., The protein tyrosine kinase JAK1 complements defects in interferon-??/?? and -?? signal transduction, Nature, vol.366, issue.6451, pp.129-135, 1993.
DOI : 10.1038/366129a0

L. Velazquez, M. Fellous, G. Stark, and S. Pellegrini, A protein tyrosine kinase in the interferon ???? signaling pathway, Cell, vol.70, issue.2, pp.313-322, 1992.
DOI : 10.1016/0092-8674(92)90105-L

S. Pellegrini, J. John, M. Shearer, I. Kerr, and G. Stark, Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway., Molecular and Cellular Biology, vol.9, issue.11, pp.4605-4612, 1989.
DOI : 10.1128/MCB.9.11.4605

N. Couturier, F. Bucciarelli, R. Nurtdinov, M. Debouverie, C. Lebrun-frenay et al., Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility, Brain, vol.134, issue.3, pp.693-703, 2011.
DOI : 10.1093/brain/awr010

I. Grumbach, E. Fish, S. Uddin, B. Majchrzak, O. Colamonici et al., Activation of the Jak-Stat Pathway in Cells That Exhibit Selective Sensitivity to the Antiviral Effects of IFN-beta Compared with IFN-alpha, Journal of Interferon & Cytokine Research, vol.19, issue.7, pp.797-801, 1999.
DOI : 10.1089/107999099313659

A. Da-silva, M. Brickelmaier, G. Majeau, A. Lukashin, J. Peyman et al., Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor

J. Sancéau, J. Hiscott, O. Delattre, and J. Wietzerbin, IFN-?? induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7, Oncogene, vol.19, issue.30, pp.3372-3383, 2000.
DOI : 10.1038/sj.onc.1203670

E. Coro and W. Chang, Type I IFN Receptor Signals Directly Stimulate Local B Cells Early following Influenza Virus Infection, The Journal of Immunology, vol.176, issue.7, pp.4343-4351, 2006.
DOI : 10.4049/jimmunol.176.7.4343

N. Manel, B. Hogstad, Y. Wang, D. Levy, D. Unutmaz et al., A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells, Nature, vol.78, issue.7312, pp.214-217, 2010.
DOI : 10.1038/nature09337

B. Guo, E. Chang, and G. Cheng, The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice, Journal of Clinical Investigation, vol.118, issue.5, pp.1680-1690, 2008.
DOI : 10.1172/JCI33342

I. Teige, A. Treschow, A. Teige, R. Mattsson, V. Navikas et al., Issazadeh-Navikas S: IFN-beta gene deletion leads to

A. Rubtsov, K. Rubtsova, A. Fischer, R. Meehan, J. Gillis et al., Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity, Blood, vol.118, issue.5, pp.1305-1315, 2011.
DOI : 10.1182/blood-2011-01-331462

E. Calderón-gómez, V. Lampropoulou, P. Shen, P. Neves, T. Roch et al., Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis, European Journal of Immunology, vol.33, issue.6, pp.1696-1708, 2011.
DOI : 10.1002/eji.201041041

S. Knippenberg, E. Peelen, J. Smolders, M. Thewissen, P. Menheere et al., Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced na??ve/memory Breg ratio during a relapse but not in remission, Journal of Neuroimmunology, vol.239, issue.1-2, pp.80-86, 2011.
DOI : 10.1016/j.jneuroim.2011.08.019

G. Brito-melo, J. Souza, E. Barbosa-stancioli, A. Carneiro-proietti, B. Catalan-soares et al., Establishing Phenotypic Features Associated with Morbidity in Human T-Cell Lymphotropic Virus Type 1 Infection, Clinical and Vaccine Immunology, vol.11, issue.6, pp.1105-1110, 2004.
DOI : 10.1128/CDLI.11.6.1105-1110.2004

A. Cross, J. Stark, J. Lauber, M. Ramsbottom, and J. Lyons, Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients, Journal of Neuroimmunology, vol.180, issue.1-2, pp.63-70, 2006.
DOI : 10.1016/j.jneuroim.2006.06.029

N. Monson, P. Cravens, E. Frohman, K. Hawker, and M. Racke, Effect of Rituximab on the Peripheral Blood and Cerebrospinal Fluid B Cells in Patients With Primary Progressive Multiple Sclerosis, Archives of Neurology, vol.62, issue.2, pp.258-264, 2005.
DOI : 10.1001/archneur.62.2.258

S. Hauser, E. Waubant, D. Arnold, T. Vollmer, J. Antel et al., B-Cell Depletion with Rituximab in Relapsing???Remitting Multiple Sclerosis, New England Journal of Medicine, vol.358, issue.7, pp.676-688, 2008.
DOI : 10.1056/NEJMoa0706383

L. Kappos, D. Li, P. Calabresi, O. Connor, P. Bar-or et al., Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, The Lancet, vol.378, issue.9805, pp.1779-1787, 2011.
DOI : 10.1016/S0140-6736(11)61649-8

A. Gottlieb, S. Kang, K. Linden, M. Lebwohl, A. Menter et al., Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis, Clinical Immunology, vol.111, issue.1, pp.28-37, 2004.
DOI : 10.1016/j.clim.2004.01.006

M. Czuczman, A. Thall, T. Witzig, J. Vose, A. Younes et al., Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.19, pp.4390-4398, 2005.
DOI : 10.1200/JCO.2005.09.018